CT-95 is a bispecific antibody targeting mesothelin-expressing cancers, engaging T cells to attack tumors. The phase 1 trial in San Antonio will evaluate CT-95's safety, tolerability, pharmacokinetics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results